Showing results (1571-1580 of 1,651) with videos related to
Sort By:
Pageof 166
Cell Reports|June 24, 2021
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7Bo Meng, Steven A Kemp, Guido Papa, et al.Nature|February 23, 2007
Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction mapSean R Collins, Kyle M Miller, Nancy L Maas, et al.EMBO Molecular Medicine|April 9, 2025
Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframeGeorgina D Barnabas, Tariq A Bhat, Verena Goebeler, et al.Lancet (London, England)|December 4, 2019
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.Physical Review Letters|January 24, 2015
First measurement of neutrino and antineutrino coherent charged pion production on argonR Acciarri, C Adams, J Asaadi, et al.Physical Review Letters|June 12, 2012
First measurements of inclusive muon neutrino charged current differential cross sections on argonC Anderson, M Antonello, B Baller, et al.Nature Communications|June 16, 2023
Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2Katherine U Gaynor, Marina Vaysburd, Maximilian A J Harman, et al.Journal of Medicinal Chemistry|September 21, 2011
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)Travis T Wager, Betty A Pettersen, Anne W Schmidt, et al.Physical Review Letters|August 16, 2006
Measurement of the asymmetry in the decay Omega+-->LamdaKappa+-->rhopi+Kappa+L C Lu, R A Burnstein, A Chakravorty, et al.The Lancet. Oncology|June 11, 2022
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R Clamp, Elizabeth C James, Iain A McNeish, et al.Pageof 166